INT12854

From wiki-pain
Revision as of 15:19, 22 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 1983
Last Reported 2007
Negated 0
Speculated 0
Reported most in Abstract
Documents 11
Total Number 11
Disease Relevance 3.25
Pain Relevance 5.28

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

carbohydrate metabolic process (Gusb) lysosome (Gusb)
Anatomy Link Frequency
small intestine 2
plasma 1
cleavage 1
large intestine 1
gut 1
Gusb (Rattus norvegicus)
Pain Link Frequency Relevance Heat
cINOD 7 99.98 Very High Very High Very High
Morphine 45 97.44 Very High Very High Very High
Opioid 5 96.28 Very High Very High Very High
Pain score 1 93.32 High High
Pain 1 91.28 High High
Bioavailability 12 91.04 High High
Inflammation 2 85.04 High High
Arthritis 2 85.04 High High
antagonist 3 77.36 Quite High
Delta opioid receptors 1 75.00 Quite High
Disease Link Frequency Relevance Heat
Cancer 9 99.46 Very High Very High Very High
Diarrhoea 9 95.52 Very High Very High Very High
Pain 1 93.08 High High
Diabetes Mellitus 37 90.56 High High
Crystal Associated Disease 2 87.12 High High
INFLAMMATION 6 85.04 High High
Toxicity 1 80.72 Quite High
Body Weight 11 78.16 Quite High
Lung Cancer 1 77.28 Quite High
Pleurisy 3 75.52 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
A decrease in ss-glucuronidase activity was detected in 67% of the subjects in the probiotic group vs. 38% in the placebo group (P = 0.06).
Negative_regulation (decrease) of ss-glucuronidase
1) Confidence 0.42 Published 2007 Journal Aliment. Pharmacol. Ther. Section Body Doc Link 17635381 Disease Relevance 0 Pain Relevance 0
In vitro study in rats showed that DGNTT significantly inhibits the activity of beta-glucuronidase (P < 0.05) and lysozyme release (P < 0.01) from neutrophils.
Negative_regulation (inhibits) of beta-glucuronidase in neutrophils
2) Confidence 0.40 Published 1995 Journal Am. J. Chin. Med. Section Abstract Doc Link 8571922 Disease Relevance 0.49 Pain Relevance 0.34
Both SAID and NSAID reduced the arylsulfatase activity released into the exudate (free activity) dose-relatedly but not the free activity of beta-glucuronidase at 3 h after carrageenin.
Negative_regulation (reduced) of beta-glucuronidase associated with cinod
3) Confidence 0.30 Published 1983 Journal Eur. J. Pharmacol. Section Abstract Doc Link 6583058 Disease Relevance 0.46 Pain Relevance 0.63
In vitro experiments provided evidence that verapamil inhibits beta-glucuronidase from E. coli with an IC(50) of 30 microM, whereas no inhibition of the rat beta-glucuronidase from small intestine was seen.
Negative_regulation (inhibits) of beta-glucuronidase in small intestine
4) Confidence 0.27 Published 2002 Journal Biochem. Pharmacol. Section Abstract Doc Link 11996900 Disease Relevance 0 Pain Relevance 0.77
In conclusion, verapamil decreased intestinal deglucuronidation of M6G by inhibiting E. coli beta-glucuronidase.
Negative_regulation (inhibiting) of beta-glucuronidase
5) Confidence 0.23 Published 2002 Journal Biochem. Pharmacol. Section Abstract Doc Link 11996900 Disease Relevance 0 Pain Relevance 0.63
Verapamil decreases glucuronidase activity in the gut.
Negative_regulation (decreases) of glucuronidase in gut
6) Confidence 0.23 Published 2002 Journal Biochem. Pharmacol. Section Title Doc Link 11996900 Disease Relevance 0 Pain Relevance 0.74
In vitro experiments provided evidence that verapamil inhibits beta-glucuronidase from E. coli with an IC(50) of 30 microM, whereas no inhibition of the rat beta-glucuronidase from small intestine was seen.
Negative_regulation (inhibition) of beta-glucuronidase in small intestine
7) Confidence 0.23 Published 2002 Journal Biochem. Pharmacol. Section Abstract Doc Link 11996900 Disease Relevance 0 Pain Relevance 0.73
As initial results pointed towards inhibition of glucuronidases by verapamil, its capability to specifically inhibit E. coli and/or rat intestinal beta-glucuronidase was assessed using altered cleavage of the model substrate 4-methylumbelliferyl-beta-D-glucuronide (MUG).
Negative_regulation (inhibit) of beta-glucuronidase in cleavage
8) Confidence 0.20 Published 2002 Journal Biochem. Pharmacol. Section Abstract Doc Link 11996900 Disease Relevance 0 Pain Relevance 0.83
In either NC or DC group, no prominent peak corresponding to quercetin aglycone appeared in the chromatogram of the extract from rat plasma treated with sulfatase H-5, which possesses both sulfatase activity and glucuronidase activity.
Negative_regulation (possesses) of glucuronidase in plasma
9) Confidence 0.09 Published 2007 Journal Journal of Clinical Biochemistry and Nutrition Section Body Doc Link PMC2127222 Disease Relevance 0.53 Pain Relevance 0
Activities of beta-glucuronidase and beta-hexoseaminidase were diminished in total homogenates and subcellular fractions from naltrexone-treated cells, suggesting an opioid-induced alteration in lysosomal enzyme trafficking.
Negative_regulation (diminished) of beta-glucuronidase associated with opioid
10) Confidence 0.05 Published 1991 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 1656025 Disease Relevance 0.07 Pain Relevance 0.51
Oral administration of antibiotics [Cancer Res 56: 3752-3757, 1996; Clin Cancer Res 7: 1136-1141, 2001] or kampo medicine [Jpn J Cancer Res 86: 978-984, 1995; Jpn J Cancer Res 86: 985-989, 1995] to decrease beta-glucuronidase activity derived from bacteria in the large intestine was also reported to be successful in preventing delayed diarrhea.
Negative_regulation (decrease) of beta-glucuronidase in large intestine associated with diarrhoea and cancer
11) Confidence 0.01 Published 2003 Journal Gan To Kagaku Ryoho Section Abstract Doc Link 12852342 Disease Relevance 1.70 Pain Relevance 0.10

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox